Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) has shared an update.
OncoSil Medical Limited has announced an investor webinar scheduled for 18 September 2025, where CEO Nigel Lange will discuss preliminary results from the PANCOSIL Investigator Initiated Study. This event highlights OncoSil’s ongoing efforts to engage with stakeholders and provide updates on their innovative cancer treatment solutions, potentially impacting their market positioning and stakeholder relations.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical (ASX:OSL) is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the intratumoural placement of Phosphorous-32 (32P) Microparticles, enhancing radiation delivery directly to tumors. OncoSil Medical’s flagship product, the OncoSil™ device, is designed for treating unresectable locally advanced pancreatic cancer and has received CE Marking approval, allowing its use in over 30 countries, including the EU, UK, Turkey, and Israel.
Average Trading Volume: 41,802
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$30.12M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.